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Abstract 
Alterations of endo/exocytic proteins have long been associated with 
malignant transformation and genes encoding membrane trafficking proteins 
have been identified as bona fide drivers of tumorigenesis. Focusing on the 
mechanisms underlying the impact of endo/exocytic proteins in cancer, a 
scenario emerges in which altered trafficking routes/networks appear to be 
preferentially involved in the acquisition of pro-metastatic traits. This 
involvement in metastasis frequently occurs through the integration of 
programs leading to migratory/invasive phenotypes, survival and resistance to 
environmental stresses, epithelial-to-mesenchymal transition, and the 
emergence of cancer stem cells. These findings might have important 
implications in the clinical setting for the development of metastasis-specific 
drugs and for patient stratification to optimize the use of available therapies. 
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Introduction 
The modern view of endocytic/exocytic membrane trafficking is that of a 
complex process embedded in virtually every aspect of cell regulation, 
including control of signaling at multiple levels [reviewed in (1)]. This view has 
led to the idea that subversion of the endomembrane traffic machinery could 
contribute to cancer, a concept that has received substantial experimental 
corroboration [reviewed in (1,2)]. However, the extent of the impact of “traffic” 
alterations in "real" cancers is still an open question. For the field to move out 
of the "proof of principle stage" and to acquire value in terms of the 
development of clinically relevant strategies, a number of issues need to be 
addressed: 
1. Although in vitro studies are critical for the elucidation of molecular 
mechanisms, more extensive analyses in real tumors are needed. Given the 
pervasive role of endo/exocytic traffic in cell physiology, one should not be too 
surprised that tampering with it might lead to a transformed phenotype in vitro 
that may, however, have little relevance in the clinical setting.  
2. In real tumors, while genetic alterations of membrane trafficking genes are 
not very common, alterations in expression levels are frequently reported. 
This situation raises questions on the suitability of whole-tissue analyses that 
are routinely performed on tumor specimens to assess expression levels. 
These analyses face several drawbacks: they overlook sample cellularity, cell 
of origin of the signal and intratumoral heterogeneity. Thus, to avoid 
misleading results, analyses at the single cell level are important. 
3. The correlation between level of expression of a gene-of-interest in a given 
tumor type and clinical-pathological parameters is often interpreted as a good 
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indicator of "some role in cancer". Frequently, however, only univariate 
analyses are reported in the literature. While this is not a disqualifying issue, 
one should bear in mind that only multivariable analysis provides proof of an 
"independent" predictor. The problem is not minor: in breast cancer, for 
instance, up to 25% of all genes and up to 90% of random multi-gene 
signatures are significant outcome predictors in univariate analysis (3).  
 With these issues in mind, we revisited the literature on endo/exocytosis 
and cancer, focusing on studies that provide: i) convincing evidence of 
endo/exocytic protein/network alterations in real tumors (i.e., genetic/driver 
alterations, analysis of over/underexpression in sufficiently sized cohorts, 
correlation with clinical parameters by multivariable analysis); and ii) extensive 
characterization of phenotypes and mechanisms (Table 1). The emerging 
scenario is that altered endo/exocytic routes and networks appear to be 
preferentially involved in the acquisition of pro-metastatic traits, frequently, 
through the integration of migratory/invasive programs with other aspects of 
cancer biology. Here, we will review selected examples to illustrate this 
concept. 
 
Induction of invasive phenotypes by endo/exocytic harnessing of 
cytoskeleton regulatory circuitries 
Cellular motility in physiological conditions and invasiveness in cancer require 
the enactment of programs involving polarized rearrangement of the actin and 
tubulin cytoskeleton (4). Critical to these programs is a subfamily of small 
GTPases, the Rho-like GTPases, to which Rac1 and Cdc42 belong. Rac1 
acts as a master regulator of cytoskeletal organization and polarized signaling 
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connected with cellular motility. Physiologically, trafficking processes are 
central to Rac1 regulation, ensuring its continuous relocalization to membrane 
sites where the execution of polarized functions take place (5). Accordingly, 
cancer-specific alterations of trafficking proteins hijack Rac1-based circuitries 
leading to aberrant migratory/invasive phenotypes. Some examples are 
provided below. 
 A major circuitry regulating Rac1 involves the Rab5A/Rab4 axis. These 
proteins belong to the family of Rab GTPases that behave as critical 
molecular switches in the regulation of membrane dynamics, including vesicle 
formation, movement, maturation, and connection with the actin and tubulin 
cytoskeleton (6). Rab5A is a master regulator of endosomal dynamics, while 
Rab4 is involved in recycling to the plasma membrane (PM) (6). Rab5A is 
overexpressed in breast cancers and is an independent predictor of 
unfavorable outcome (7). Phenotypically, Rab5A overexpression can be 
correlated with increased invasiveness in vitro and in vivo, extension of 
invadosomes (actin protrusions involved in the coupled processes of 
extracellular matrix degradation and cell motility), and - importantly - 
conversion of in situ carcinomas to invasive carcinomas in vivo (7). The 
molecular action of Rab5A in this context is two-fold. Firstly, it promotes the 
encounter on early endosomes of Rac1 with a specific activator, the guanine 
exchange factor (GEF) Tiam1, after which Rac1 is recycled to restricted 
regions of the PM where it controls polarized protrusion of lamellipodia and 
directed migration (5). Secondly, Rab5A controls the trafficking of 
metalloproteases and integrins (7). In this latter circuitry, Rab4, which is also 
overexpressed in breast cancer, acts downstream of Rab5A by recycling 
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metalloproteases and integrins to regions of the PM where invadosomes will 
form (7).  
 A different pathway relying on another Rac1-GEF - Vav1 - is subverted in 
pancreatic cancer. In this case, the protein involved is Dynamin 2 (Dyn2), 
whose major function is to control fission of endocytic vesicles [reviewed in 
(8)]. Dyn2 is overexpressed in pancreatic ductal carcinomas and its 
overexpression promotes a migratory/invasive phenotype in vitro and in vivo 
(9). Mechanistically, this phenotype is not due to the canonical role of Dyn2 in 
vesicle fission, but rather to its direct interaction with Vav1 (10). Dyn2 
stabilizes Vav1 by protecting it from proteasomal degradation, which 
presumably leads to Rac1 activation (10). Interestingly, Vav1 is also 
overexpressed in pancreatic cancer due to demethylation of its gene promoter 
and is an independent predictor of survival (11).  
 In addition to the upstream regulation of Rac1, endocytic proteins also 
participate in Rac1 effector function. This is the case of Synaptojanin2 
(SYNJ2), a phosphoinositide phosphatase, which binds to activated Rac1 and 
mediates effects of the latter on cell motility and endocytosis (12). The SYNJ2 
gene is part of the 6q25 breast cancer amplicon and its overexpression 
predicts poor prognosis in some breast cancer subtypes (13). Overexpression 
of SYNJ2 increases cell migratory/invasive phenotypes in vitro and in vivo, 
and its silencing leads to impairment of protrusive/invasive structures (13), 
compatible with its role as a Rac1 effector. 
 A final example of a cancer-altered endocytic protein functioning as a Rho-
subfamily GTPase effector is CIP4 (CDC42-Interacting Protein 4). CIP4 
belongs to the superfamily of BAR (Bin/Amphiphysin/Rvs) domain proteins 
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that couple curvature of the membrane with re-organization of the membrane-
associated actin cytoskeleton (14). CIP4 is an effector of Cdc42, another Rho-
like GTPase critical to actin dynamics, migration and endocytosis that is also 
frequently altered in cancer. CIP4 overexpression in breast cancer represents 
an independent predictor of disease outcome, being associated with poorer 
prognosis and metastasis (15,16). Mechanistically, this is due to increased E-
cadherin internalization leading to cell scattering and improved actomyosin 
contractility (16). 
 
Rab-centered circuitries selected in cancer integrate 
motility/invasiveness with survival/resistance to environmental stresses 
The ability to metastasize is linked to the acquisition of a number of 
characteristics, including increased motility and resistance to anoikis and 
environmental stresses, such as low nutrient availability. Cancer-detected 
alterations of Rab25- and Rab1A-dependent signaling exemplify how the 
acquisition of these characteristics might happen. 
 Rab25, belonging to the Rab11 subfamily of Rabs involved in endosomal 
recycling, is the driver gene of amplicon 1q22 in breast and ovarian cancers, 
and its overexpression has been linked to resistance to apoptosis and anoikis 
(17). Evidence that Rab25 is involved in cancer cell dissemination derives 
from its role in the trafficking of the adhesive receptor integrins. 
Overexpression of Rab25 stimulates an invasive mode of migration based on 
the formation of long pseudopods. At the tip of the pseudopods, Rab25-
positive vesicles promote α5β1 integrin treadmilling that, in turn, favors 
persistent and directed cell migration (18). Interestingly, Rab25 
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overexpression is not sufficient to transform immortalized/non-tumorigenic 
cells (17,19,20); rather it stimulates the acquisition of invasive properties in 
already transformed cells. 
 Rab25 integrates invasiveness with other pro-metastatic programs that 
help invasive cells elude environmental stresses. In low nutrient conditions, 
inhibition of mTORC1 results in the accumulation of  α5β1 integrin on late 
endosomes/lysosomes and, in tumors characterized by a potentiated Rab25-
circuitry, this might promote integrin recycling and cell invasion (21). Under 
similar conditions, Rab25 stimulates glucose uptake, through direct binding to 
and activation of AKT, resulting in higher glycogen synthesis and elevated 
ATP levels, thereby providing cancer cells with an alternative energy source 
(20).  
 Depending on the context, Rab25 might also behave as a tumor 
suppressor (19). In a cohort of human colorectal cancers, Rab25 levels 
decrease in a stage-dependent manner and correlate with reduced survival in 
univariate analysis (22). In addition, while, Rab25-KO mice do not exhibit 
spontaneous tumors, they display increased incidence of colonic neoplasia 
when crossed with an APCMin/+ genetic background. In these tumors, 
localization of β1 integrin to the lateral membrane of intestinal cells is severely 
reduced (22). As mislocalization of β1 causes intestinal hyperplasia (23), loss 
of Rab25-mediated β1 trafficking in intestinal epithelial cells might contribute 
to tumor development by affecting cell polarity (22).  
 Notably, downstream effectors of Rab25 are also altered in cancer and are 
associated with the acquisition of pro-metastatic phenotypes. This is the case 
of the Rab11-family effector – Rab coupling protein (RCP), CLIC3 and 
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Tensin1 (21,24,25) (Table 1). RCP is the driver of amplicon 8p11 in breast 
cancer and its overexpression predicts metastatic recurrence (26). In the 
recycling pathway, RCP acts as a scaffold for α5β1 integrin and EGFR, 
allowing their coordinated re-localization to the elongating pseudopods that 
characterize β1-dependent 3D invasive migration (25). Interestingly, RCP 
appears to represent a point of convergence of different cancer pathways, 
since mutant, gain-of-function, p53 proteins can drive cancer cell invasion by 
exploiting RCP (27). These mutant p53 proteins promote the binding of RCP 
to α5β1, by as yet unclear mechanisms, thus, stimulating the coordinated 
recycling/relocalization of EGFR and α5β1 integrin to the PM (27).  
 Rab1A-dependent signaling represents another example of how invasive 
phenotypes and sensitivity to nutrients can be coordinately derailed in cancer. 
Rab1A, a GTPase involved in endoplasmic reticulum (ER)-to-Golgi transport, 
is overexpressed in colon cancer and predicts poor outcome and cancer 
invasiveness (28). By sensing amino acid levels, Rab1A becomes activated 
and binds to mTORC1, thereby, promoting proliferation and cellular 
transformation. Interestingly, the circuitry requires a Rab1A-dependent 
physical association with the Golgi to be functional, confirming the link 
between endomembrane dynamics and nutrient sensing. It is tempting to 
speculate that the potentiation of the Rab1A/mTORC1 axis, observable in 
colon cancers, augments sensitivity to amino acids, thereby reducing the 
effective concentration of these nutrients needed to sustain cell proliferation. 
This advantage might however become an "Achilles’ heel" for the tumor, as it 
has been shown that colon cancer cell lines overexpressing Rab1A become 
addicted to amino acids (28). We will discuss this issue further below. 
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Membrane traffic, epithelial-to-mesenchymal transition and cancer stem 
cells 
Epithelial-to-mesenchymal transition (EMT) is a complex transcriptional 
program enacted by cells that undergo a switch from an epithelial to a 
mesenchymal/migratory state. In physiology, EMT is critical for embryonic 
development and tissue repair; however, its aberrant activation is linked to 
pathological conditions, first and foremost cancer (29). Recent work, 
pioneered in Weinberg's lab, has highlighted a major role of EMT in the 
emergence of cancer stem cells (CSC). These cells are not only the initiators 
of cancer, by definition, but also represent the subpopulation of cells most 
likely responsible for metastasis and resistance to therapy [reviewed in (30)]. 
While these findings blur the traditional boundaries between cancer initiation 
and progression, they offer an additional angle to rationalize the impact of 
endo/exocytosis in cancer. Trafficking networks are critical in regulating the 
activity of signaling pathways leading to EMT, such as those activated by 
TGFβ and WNT, or in modulating the dynamics of adhesion molecules 
involved in the maintenance of epithelial polarity, such as E-cadherin 
[reviewed in (31)]. Here following, we will analyze the case of Numb and of 
Rab2A.  
 Numb sits at the intersection of multiple functions including cell fate 
decisions, maintenance of stem cell (SC) compartments, regulation of cell 
polarity, adhesion and migration [reviewed in (32)]. At the molecular level, 
Numb is involved in formation of endocytic vesicles and in their recycling to 
the PM (32). In breast cancer, Numb is a tumor suppressor whose under-
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expression represents an independent predictor of unfavorable prognosis 
(33). Loss of Numb expression leads to EMT and to the emergence of CSCs 
(34); effects that can be mechanistically linked to at least three "points of 
action". First, by controlling endocytosis/recycling of E-cadherin and the 
proper localization of the Par3 complex, Numb regulates epithelial polarity, 
adherens junctions and tight junctions (35). Second, Numb antagonizes the 
signaling receptor Notch by controlling its endocytosis and trafficking (36). 
Loss-of-Numb leads to unchecked Notch activity, which in cooperation with 
other pathways, may lead to EMT [reviewed in (37)]. Finally, Numb stabilizes 
p53 (33). This latter activity is particularly interesting: Numb binds to and 
inhibits the ubiquitin ligase Mdm2, which, in turn, is responsible for p53 
ubiquitination and proteasomal degradation. Thus, loss-of-Numb results in 
decreased levels and activity of p53 (33). This effect of Numb on p53 stability 
is likely to be highly relevant to cancer, since p53 ablation in in vivo model 
systems leads to expansion of the mammary SC compartment accompanied 
with the emergence of CSCs (38). Indeed, the effects of loss-of-Numb on 
CSCs and EMT are mediated by loss of p53 protein (34). It is, however, 
unclear whether the control of Numb over p53 is linked to its function in 
membrane trafficking: a possibility that warrants investigation especially in 
light of the connection between p53 subversion and the RCP-mediated 
endocytic/trafficking pathways in cancer. 
 Rab2A is amplified and overexpressed in breast cancer (39,40) and it 
represents an independent predictor of metastasis (40). Rab2A controls ER-
to-Golgi transport (41); however, it is also present on late endosomes where it 
interacts with VSP39 (40,42), a component of the homotypic fusion and 
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vacuole protein sorting complex (HOPS) that is responsible for fusion of late 
endosomes with lysosomes (43). Not surprisingly, therefore, hyper-activation 
of Rab2A in breast cancer cells affects more than one trafficking step. On late 
endosomes, it stimulates VSP39-dependent post-endocytic recycling of the 
metalloprotease MT1-MMP to the PM, promoting matrix degradation. At the 
Golgi, it delays E-cadherin trafficking to the cell surface reducing junctional 
stability and cell compaction. The resulting combined effect is increased 
cellular invasiveness (40). The acquisition of an invasive phenotype by Rab2A 
overexpressing cells might be, however, part of a more complex program, 
connected with EMT. Indeed, increased Rab2A expression leads to the 
acquisition of EMT traits and to the expansion of the CSC compartment in 
mammary model systems (39). This function is mediated by prolongation of 
signaling by ERK1/2, to which Rab2A binds and protects from deactivation, 
and is controlled by the prolyl isomerase Pin1 that increases the transcription 
of Rab2 through yet unknown mechanisms. Interestingly, Pin1 is itself 
overexpressed in breast cancer and controls the normal and neoplastic SC 
compartment (44). Finally, Numb- and Rab2A-controlled pathways might 
converge in the fine-tuning of cellular responses leading to EMT, since it has 
been shown that Pin1 and Notch are involved in a feed forward loop that 
potentiates the level and activity of both proteins (45). 
 
Outlook: an endo/exocytosis centered strategy towards a metastasis-
specific therapy 
In this review, we focused on trafficking proteins and pathways altered with 
reasonable frequency and with a reasonable degree of confidence in human 
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tumors. The goal was to distill from a vast amount of literature paradigmatic 
examples of clinical interest, especially in the perspective of targeted 
therapies.  
 At the biological level, as discussed, cancer-altered endo/exocytic proteins 
seem to be preferentially associated with pro-metastatic phenotypes, most 
notably increased migration/aggressiveness, rather than with "canonical" 
hyperproliferative phenotypes. Mechanistically, the pro-metastatic phenotypes 
are mainly caused by alterations in the delivery of critical effectors to the PM, 
including adhesion molecules (integrins and cadherins), metalloproteases, 
and regulators of actin dynamics (such as Rac1). These observations uphold 
the emerging concept of endocytosis/exocytosis cycles (EECs) acting to 
maintain homeostatic levels of PM proteins and, when needed, to rapidly 
deliver cargoes to regions of the PM where polarized functions must occur (1). 
At the same time, the appearance of invasive properties is frequently 
accompanied by other phenotypes related to survival and resistance to 
environmental stresses, which can also be considered part of the "metastatic 
toolkit”.  
 One important question is whether endo/exocytic proteins represent viable 
targets for the development of molecular therapies. This possibility could be 
actualized through two major strategies. On the one hand, endo/exocytic 
proteins directly involved in cancer might be targetable in themselves as 
suggested by the successful identification of specific inhibitors of the 5'-
phosphatase activity of SYNJ2 that prevent in vitro cell invasion (13). On the 
other hand, the trafficking "signature" of some cancers could be used to 
stratify patients and optimize therapies based on the unique characteristics 
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conferred by endo/exocytic alterations to cancer cells. The proof-of-principle 
of this approach is represented by the drug responsiveness of colorectal 
cancer cells (CRCs) overexpressing Rab1A. As discussed, these cells are 
addicted to amino acid-induced mTORC1 activity (28). As a result, xenografts 
established from Rab1A-high CRCs were highly sensitive to the mTORC1 
inhibitor rapamycin, while Rab1A-low CRCs were not (28). 
 Finally, the emerging connection between alteration of endo/exocytosis and 
induction of EMT/emergence of CSCs also harbors therapeutic implications. 
In recent years, considerable effort has been directed towards high-
throughput profiling of human tumors. One of the most unexpected findings 
that emerged from these studies is that some tumors are metastatically 
“imprinted” ab initio (46); an idea that contrasted the “canonical” view of tumor 
progression in which the emergence of metastatic subpopulations represents 
a late event in the natural history of the tumor. Nevertheless, these results 
received substantial molecular confirmation from studies showing how EMT 
can give rise to CSCs, which fuel both tumor growth (due to their self-renewal 
ability) and metastasis (due to their migratory/invasive ability) (30). An 
intimate link between migration and tumor growth was proposed recently on 
the basis of theoretical modeling showing that cellular dispersal and turnover 
can account for potent selective advantages within a tumor mass (47). The 
combined analysis of these findings argue for a paramount role of migration in 
the natural history of the tumor, both in its primary location and in its 
metastatic ramifications. In this framework, endo/exocytic proteins, because of 
their ability to network circuitries controlling migration, polarity, proliferation 
and survival, appear to be uniquely posited to represent interesting targets for 
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anti-CSC and anti-metastatic therapies. 
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Table 1. Examples of trafficking proteins altered in cancer 
 
GENE FUNCTION ALTERATION TUMOR TYPE 
RAB5A Rab GTPase O Breast 
DYN2 
(Dynamin 2) 
GTPase 
(fission) 
O Pancreas 
SYNJ2 
(Synaptojanin 2) 
Phospoinositid
e phosphatase 
A Breast 
CIP4 Cdc42 effector O Breast, Lung 
RAB25 Rab GTPase A Breast, Ovary 
RCP/RAB11FIP1 Rab Effector A Breast 
CLIC3 Rab25 effector O Ovary 
RAB1A Rab GTPase O Colon 
RAB2A Rab GTPase A Breast 
NUMB Adapter U Breast, Lung 
SH3GL1 
(Endophilin A2) 
Adapter O, M(T) Breast, Leukemia 
RAB35 Rab GTPase M Lymphoma, Lung, 
Uterus 
GOLPH3 Golgi protein A Multiple 
CBL E3 ligase M Leukemia 
CAV1 (caveolin) Coat protein U,M,O Multiple 
DAB2 Adapter U Multiple 
HIP1 Adapter O, M(T) Multiple 
NDRG1 Rab4 effector U Prostate, Breast, Lung 
Clathrin Coat protein M(T) Lymphomas, Kidney 
 
The Table displays examples of endocytic/exocytic proteins altered in human 
cancers. Proteins reviewed in details are shaded. The list is not 
comprehensive and additional hits (and detailed referencing to the proteins 
not covered in this review) can be found in (1), (2) and (48). 
Alteration: A, amplified; O, overexpressed (in the absence of reported gene 
amplification); U, underexpressed; M, mutated (point mutations); M(T), 
mutated (translocation). 
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